What to know
- Presentation Day/Time: Friday, April 25, 9:00–10:25 am
- Presenter: Avnika Amin, PhD, MSPH, EIS officer assigned to the National Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases
What did we do?
- We conducted a systematic review and meta-analysis to inform the Advisory Committee on Immunization Practices' (ACIP's) deliberations regarding GlaxoSmithKline's (GSK's) new pentavalent vaccine (MenABCWY) for meningococcal disease versus currently recommended serogroup B (MenB) and quadrivalent (MenACWY) vaccines.
What did we find?
- We analyzed data from seven clinical trials among 8,141 healthy participants. After one dose of MenABCWY or MenACWY, participants were similarly likely to be seroprotected against serogroups A, C, W, and Y.
- After two doses of MenABCWY or MenB, MenABCWY recipients had slightly less seroprotection for some serogroup B antigens, though the evidence suggested overall good immunogenicity.
- Serious adverse events were rare, with similar frequency after administration of MenABCWY, MenB, and MenACWY.
Why does it matter?
- MenABCWY confers similar short-term immunity and has comparable, low risk of SAEs versus MenB or MenACWY.
- GSK's MenABCWY vaccine may be a promising option for protecting adolescents against meningococcal disease.
***This presentation has updated data that will be shared at the EIS Conference.
Abstract Category: Vaccines